logo

Review Timeline | CrossMark Policy | ClinMed Features
   

Need a supporting hand in manuscript formatting? Write to our team.
Assistance in presubmission | editorialoffice@clinmedjournals.org

     

Review Article  |   Volume 4, Issue 1

Angiogenesis Inhibitor Induced Thromboembolism in Cancer Patients

Neeharik Mareedu and Carmen P Escalante
Abstract

Therapy with Angiogenesis Inhibitors (AIs) is a newer targeted approach in treating cancers. It gained popularity in the past decade because of better outcomes and fewer side effects when compared to conventional chemotherapeutic agents. These agents act by inhibiting the VEGF pathway and inhibit vasculogenesis, thus shutting off the nutrient supply to the continuously multiplying tumor cells.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/1410080

Review Article  |   Volume 4, Issue 1

The Role of Notch Signaling in Liver Diseases: Contribution to Development and Cancer

Kazunori Kawaguchi, Masao Honda and Shuichi Kaneko
Abstract

Liver tissue consists of several types of cells such as hepatocytes, endothelial cells, stellate cells, cholangiocytes, and immune cells, all with essential functions. The liver plays an important role in metabolism because its cells act on a variety of substances, transforming them into metabolic products essential for life and the production of waste products.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/1410079

Original Article  |   Volume 4, Issue 1

In Vitro Reaction of Cells Derived from Human Normal Lung Tissues to Carbon-Ion Beam Irradiation

Naoko Okano, Takahiro Oike, Jun-ichiSaitoh, KatsuyukiShirai, Masato Enari, TohruKiyono, MayuIsono, Kota Torikai, Tatsuya Ohno and Takashi Nakano
Abstract

Radiation-induced lung injury (RILI) is a serious concern in carbon-ion radiation therapy (CIRT) for thoracic malignancies. To estimate the induction of RILI after CIRT, translation of evidence in X-ray radiation therapy to CIRT is of great importance. However, the relative biological effectiveness (RBE) of carbon-ion beams in normal lung tissues is not fully elucidated, making the translation difficult.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/1410078

Original Article  |   Volume 4, Issue 1

Acetylation of α-tubulin by a Histone Deacetylase Inhibitor, Resminostat, Leads Synergistic Antitumor Effect with Docetaxel in Non-Small Cell Lung Cancer Models

Hiroaki Konishi, Akimitsu Takagi, Hiroyuki Takahashi, Satoru Ishii, Yu Inutake and Takeshi Matsuzaki
Abstract

There is a growing body of clinical evidence to demonstrate that inhibition of histone deacetylase is effective in the treatment of various types of cancer. We examined whether acetylation of a non-histone protein α-tubulin was induced by resminostat and this acetylation exerts combination effects with docetaxel since α-tubulin was a target of docetaxel.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/1410077

Original Article  |   Volume 4, Issue 1

Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: a Multicenter Japanese Retrospective Study

Masako Sato, Masato Takahashi, Kenichi Watanabe, Nobumoto Tomioka, Mitsugu Yamamoto, Yoshiaki Narita, Hiroaki Kato, Masaru Abe, Yukiko Tabata, Masaya Kawada, Motoshi Tamura, Mitsuchika Hosoda, Motoi Baba, Kazuhiro Ogasawara, Tomohiro Oshino, Hiromitsu Akabane, Yasuhiro Suzuki, Masatoshi Kadoya, Kazuhiro Iwai, Yumi Okawa, Kenjiro Misu, Kazuomi Ichinokawa and Hiroko Yamashita
Abstract

Trastuzumab emtansine (T-DM1) is currently approved for the treatment of patients with HER2-positive metastatic breast cancer after failure of prior anti-HER2 therapies. However, the efficacy of T-DM1 in patients who received pertuzumab, and in those patients with brain metastases, is currently unclear.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/1410076